NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 20.57 against a street estimate of 8.67 — a beat of 137.3%.
with an average price target of ₹1,661.20.
MIXED DBF grew 14% with insulin and semaglutide strong; margins compressed 300bps due to biologics mix shift. Swiss Parenterals softens outlook; FY27 guidance maintained at 14% (300bps ahead of 11% market). Bhopal facility commercializes August. Q1 FY27 Consolidated revenue +13% YoY; DBF +14%; exports flattish-to-low single-digit. Analysts focused on underperforming OAD (+2%) and cardiac (+11% vs market +15%), Swiss Parenterals slowdown, and semaglutide adoption headwinds. Management attributed therapy misses to prior product bans and field lapses (now refocused), Swiss to facility remediation, and semaglutide to patient hesitation—not supply or price—with turnaround confidence anchored on past execution. 2026-07-29…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Eris Lifesciences Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.